Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | DDO | Q99489 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238496 | 0.87 | GABRA1 (0.57) | CYP1A2GABRA1GABRB2ALDH1A1DAO | |
| SCHEMBL7754391 | 0.86 | CYP1A2 (0.62) | CYP1A2CYP2A6GABRA1GABRB2ALDH1A1 | |
| SCHEMBL7828579 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP2A6GABRA1GABRB2ALDH1A1 | |
| SCHEMBL16775293 | 0.83 | BRD4 (0.44) | CYP1A2CYP2A6GABRA1GABRB2ALDH1A1 | |
| SCHEMBL10900222 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2A6GABRA1GABRB2ALDH1A1 | |
| SCHEMBL15345377 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2A6ALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL14496815 | 0.79 | CYP1A2 (0.59) | CYP1A2CYP2A6ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL29463284 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1TSHRAHR | |
| SCHEMBL424167 | 0.79 | CYP1A2 (1.00) | CYP1A2CYP2A6ALDH1A1TSHRAHR | |
| SCHEMBL24110399 | 0.79 | CYP1A2 (0.46) | CYP1A2CYP2A6GABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| US-5770683-A | Preparation process of polyhydroxycarboxylic acid | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0710684-A2 | Preparation process of polyhydroxycarboxylic acid | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-4740647-A | COPPER ALUMINUM BORATE TO CATALYZE DEHYDROCYCLIZATION OF ALKENYL AROMATIC COMPOUND | AMOCO CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| US-4212711-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4212710-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4148696-A | Electrochemical oxidation of activated alkyl aromatic compounds | UOP INC. (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885CYP2A6 1327/4885GABRA1 4342/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP1A2 1415/4885CYP2A6 1388/4885GABRA1 4299/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CYP1A2 1161/4885CYP2A6 1193/4885GABRA1 4586/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885CYP2A6 1296/4885GABRA1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.